Anti-Mouse CD223 (LAG-3) - Purified

Leinco Technologies
Product Code: LEI-C2155
Product Group: Primary Antibodies
CodeSizePrice
LEI-C2155-100ug100 ug£179.00
Quantity:
LEI-C2155-500ug500 ug£276.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Rat
Antibody Isotype: IgG1
Antibody Clonality: Monoclonal
Antibody Clone: C9B7W
Regulatory Status: RUO
Target Species: Mouse
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Flow Cytometry
  • Immunohistochemistry- Frozen Section (IHC-F)
  • Spatial Biology
Shipping:
2-8°C
Storage:
This purified antibody is stable when stored at 2-8°C. Do not freeze.

Images

1 / 1

Further Information

Antigen Distribution:
CD223 is expressed on T regulatory cells, activated T cells and NK cells.
Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Purified
Format:
This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Purified Recombinant Mouse LAG-3
Long Description:
LAG-3 is a 70-kD, type-I transmembrane glycoprotein within the Ig superfamily with four extracellular Ig-like domains (D1 to D4) and is structurally homologous to CD4. LAG-3 is a cell surface molecule with various biologic effects on T cell function. It has been reported to be involved in Treg suppressive function. It negatively regulates cellular proliferation, activation, and homeostasis of T cells, in a similar manner to CTLA-4 and PD-1. Human LAG-3 is approximately 70% homologous with murine LAG3, and it binds MHC class II molecules with higher affinity than CD4. As an immune checkpoint receptor, LAG-3 is the target of various drug development programs seeking to expand treatments for cancer and autoimmune disorders. In its soluble form, LAG-3 is being developed as a cancer drug. As an antagonist, LAG-3 antibody can activate T effector cells via the downregulation of the LAG-3 inhibiting signal into pre-activated LAG-3+ cells. In addition, it can inhibit antigen-specific Treg suppressive activity. As an agonist antibody, it can be used to diminish an autoimmune response and is currently being investigated for the treatment of plaque psoriasis.
NCBI Gene:
16768
Target:
CD223